{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:58:39Z","timestamp":1761674319729,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00464-021-08711-8","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T22:02:40Z","timestamp":1631743360000},"page":"1666-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EUS-guided fiducial marker insertion for radiotherapy in advanced esophageal carcinoma: submucosal insertion may lead to less migration when compared to intratumoral insertion"],"prefix":"10.1007","volume":"36","author":[{"given":"Shannon Melissa","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hon Chi","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Leonard","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy Chor Man","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Wai Yan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enders Kwok Wai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-8035","authenticated-orcid":false,"given":"Anthony Yuen Bun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"8711_CR1","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090\u20131098","journal-title":"Lancet Oncol"},{"key":"8711_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","volume":"8","author":"V Gebski","year":"2007","unstructured":"Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226\u2013234","journal-title":"Lancet Oncol"},{"key":"8711_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/cncr.27927","volume":"119","author":"R Shridhar","year":"2013","unstructured":"Shridhar R, Almhanna K, Hoffe SE et al (2013) Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis. Cancer 119:1636\u20131642","journal-title":"Cancer"},{"key":"8711_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clon.2010.12.001","volume":"23","author":"S Gwynne","year":"2011","unstructured":"Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T (2011) Definitive chemoradiation for oesophageal cancer\u2013a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 23:182\u2013188","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"8711_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/0284186X.2019.1588991","volume":"58","author":"M Machiels","year":"2019","unstructured":"Machiels M, Jin P, van Hooft JE et al (2019) Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers. Acta Oncol 58:943\u2013950","journal-title":"Acta Oncol"},{"key":"8711_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.prro.2012.02.006","volume":"3","author":"DC Fernandez","year":"2013","unstructured":"Fernandez DC, Hoffe SE, Barthel JS et al (2013) Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol 3:32\u201339","journal-title":"Pract Radiat Oncol"},{"key":"8711_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3748\/wjg.v23.i5.751","volume":"23","author":"T DaVee","year":"2017","unstructured":"DaVee T, Ajani JA, Lee JH (2017) Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol 23:751\u2013762","journal-title":"World J Gastroenterol"},{"key":"8711_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.gie.2009.10.027","volume":"71","author":"PB Cotton","year":"2010","unstructured":"Cotton PB, Eisen GM, Aabakken L et al (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 71:446\u2013454","journal-title":"Gastrointest Endosc"},{"key":"8711_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228\u201347","journal-title":"Eur J Cancer."},{"key":"8711_CR10","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1200\/JCO.2005.20.644","volume":"23","author":"CJ Lightdale","year":"2005","unstructured":"Lightdale CJ, Kulkarni KG (2005) Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 23:4483\u20134489","journal-title":"J Clin Oncol"},{"key":"8711_CR11","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1055\/s-0034-1392274","volume":"3","author":"D Chavalitdhamrong","year":"2015","unstructured":"Chavalitdhamrong D, DiMaio CJ, Siersema PD, Wagh MS (2015) Technical advances in endoscopic ultrasound-guided fiducial placement for the treatment of pancreatic cancer. Endosc Int Open 3:E373\u2013E377","journal-title":"Endosc Int Open"},{"key":"8711_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.gie.2015.03.1972","volume":"82","author":"M Machiels","year":"2015","unstructured":"Machiels M, van Hooft J, Jin P et al (2015) Endoscopy\/EUS-guided fiducial marker placement in patients with esophageal cancer: a comparative analysis of 3 types of markers. Gastrointest Endosc 82:641\u2013649","journal-title":"Gastrointest Endosc"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-021-08711-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T16:23:04Z","timestamp":1642090984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-021-08711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["8711"],"URL":"https:\/\/doi.org\/10.1007\/s00464-021-08711-8","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"type":"print","value":"0930-2794"},{"type":"electronic","value":"1432-2218"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Anthony Y. B. Teoh is a consultant for Boston Scientific, Cook, Taewoong and Microtech Medical Corporations. Drs. S Chan, T Tse, H Yip, D Chan, D Lam, P Chiu, E Ng have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}